ReviewSignal transduction and targeted therapy2026
Antiviral drug discovery and development: challenges and future directions.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Establishment of an in vitro human blood-brain barrier model for antiviral screening against neurotropic viruses.Fluids and barriers of the CNS · 2026Article
- Special Issue "Antiviral Drugs Discovery".International journal of molecular sciences · 2026Article
- The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages.International journal of molecular sciences · 2026Article
- Novel Compounds as SARS-CoV-2-Related 3C-Like Protease Inhibitors for Treating Coronavirus Infections.ACS medicinal chemistry letters · 2026Article
- Novel Compounds as SARS-CoV-2-Related 3C-Like Protease Inhibitors for Treating Coronavirus Infections.ACS medicinal chemistry letters · 2026Article
- Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.Molecules (Basel, Switzerland) · 2026Article
- Virus-Induced Intestinal Barrier Injury: Mechanisms and Therapeutic Perspectives.Veterinary sciences · 2026Review
- Novel Compounds as SARS-CoV‑2 Main Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections.ACS medicinal chemistry letters · 2026Article
- Novel Compounds as SARS-CoV‑2 Main Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections.ACS medicinal chemistry letters · 2026Article
- Novel Compounds for Inhibiting Viral Replication and Treating and/or Preventing Coronavirus Infections.ACS medicinal chemistry letters · 2026Article
- Review
- Gold Nanoparticles for Antiviral Applications: Design Principles, Surface Engineering, and Mechanistic Insights.Pharmaceutics · 2026Review
- Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines · 2026Review
- Structural analysis of the flexibility of the Ubl2 domain within the papain-like protease of SARS-CoV-2.Acta crystallographica. Section F, Structural biology communications · 2026Article
- Glycyrrhizic Acid-Modified Gold Nanoparticles Show Inhibitory Activity Against PRRSV and SARS-CoV-2 Pseudovirus In Vitro.Viruses · 2026Article
- Opening the black box: insights into ubiquitin-mediated control of innate antiviral immunity and AI-enhanced therapeutics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has stimulated extensive endeavors toward the development of therapeutic interventions targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human proteins for viral infection control, encompassing numerous potential drugs and thousands of patients participating in clinical trials. These concerted efforts have resulted in significant advancements in antiviral drug discovery and development. In this review, we present a comprehensive timeline detailing the development of antiviral drugs, tracing the progression from early viral inhibitors to modern broad-spectrum antiviral agents. We also outline the current status of advancements in antiviral drug discovery, encompassing target-based strategies, innovative mechanism-based approaches, and pharmacokinetic optimization. Furthermore, we discuss the challenges and future prospects gained from COVID-19 and other infectious diseases, covering knowledge of artificial intelligence strategies, the utilization of medicinal chemistry tools, and advancements in nanotechnology applications. The application of artificial intelligence in drug discovery is increasingly prevalent, particularly in the areas of protein structure prediction, drug target identification, and bioactivity forecasting. Nanotechnology has played a crucial role in the delivery of antiviral drugs and the development of vaccines, exemplified by the use of lipid nanoparticles in mRNA vaccines. Additionally, we highlight potential future directions for drug discovery, such as targeting membraneless organelles (liquid‒liquid phase separation).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.